Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 2:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,711 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 2
Interventions
Mobile Health Care Environment (MHCE)
Other
Lead sponsor
Clemson University
Other
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Nellis Air Force Base, Nevada • Tacoma, Washington
Conditions
Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Arthritis
Interventions
Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
Other
Lead sponsor
Proove Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Beverly Hills, California • Fresno, California • La Jolla, California + 23 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Diego, La Jolla, California • Gainesville, Florida
Recruiting Not applicable Interventional Accepts healthy volunteers

Neuromodulation for Metabolic Dysfunction

NCT07597161
Conditions
Spinal Cord Injuries (SCI), Prediabetes / Type 2 Diabetes
Interventions
Transcutaneous Spinal Cord Stimulation (tSCS), Sham transcutaneous spinal cord stimulation (tSCS)
Device
Lead sponsor
Rahul Sachdeva
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Type 2 Diabetes Mellitus
Interventions
Glargine, Lispro, Dexcom G6
Drug · Device
Lead sponsor
Sandra Sobel
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Laparoscopic sleeve gastrectomy, Intensive medical management
Procedure · Behavioral
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 3 Interventional Accepts healthy volunteers Results available

RISE Pediatric Medication Study

NCT01779375
Conditions
Prediabetes, Type 2 Diabetes
Interventions
Metformin, Glargine
Drug
Lead sponsor
RISE Study Group
Network
Eligibility
10 Years to 19 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
4
States / cities
Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

NCT00615212
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK376501, Midazolam, Rosiglitazone, Flurbiprofen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Diabetes Mellitus, Obesity
Interventions
Trodusquemine (MSI-1436)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Non-alcoholic Steatohepatitis
Interventions
Placebo, PF-06835919
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
86
States / cities
Gilbert, Arizona • Tempe, Arizona • Anaheim, California + 50 more
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Completed No phase listed Observational

Microbiome Insulin Sensitivity Study

NCT03120871
Conditions
Obesity, Insulin Resistance, Type2 Diabetes
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years · Female only
Enrollment
54 participants
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Dulaglutide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
70,000 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Conditions
Type 2 Diabetes Mellitus
Interventions
INT131 besylate, Pioglitazone HCl, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
59
States / cities
Carmichael, California • Los Angeles, California • San Diego, California + 48 more
Conditions
Collaborative Implementation Intentions, Individual Implementation Intentions, Information Only Control Condition
Interventions
Collaborative implementation Intentions, Individual implementation Intentions, Control
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Type 2 Diabetes
Interventions
exenatide once weekly, basal insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
6,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV, Diabetes, Hyperglycemia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation and Glucose Metabolism

NCT01117311
Conditions
Type 2 Diabetes, Obesity, Gastric Emptying
Interventions
VNB on, VNB off
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
taVNS, Sham taVNS
Device
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Las Cruces, New Mexico
Conditions
Diabetes Mellitus, Type 2, Patient Engagement, Patient Education
Interventions
Diabetes Self-Management Behaviors
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

The LoBAG Diet and Type 2 Diabetes Mellitus

NCT02717078
Conditions
Type 2 Diabetes Mellitus
Interventions
Diet Therapy
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Type2diabetes, Diabetic Kidney Disease
Interventions
Investigational Product - MIB 626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes Mellitus
Interventions
Proteus Sustained Behavior Change system, Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Device · Drug
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts